7,228 press releases indexed under healthcare.
BRISBANE, Australia, 2026-09-05 — /EPR Network/ — Short answer: retain only the data needed for a defined clinical, legal, security, or operational purpose, for the shortest [read full press release...]
BRISBANE, Australia, 2026-09-05 — /EPR Network/ — Clinical workflow automation can help a GP turn a consultation conversation into a structured draft note, referral or [read full press release...]
BRISBANE, Australia, 2026-09-05 — /EPR Network/ — An allied health AI scribe can turn a therapy conversation into a structured draft progress note, assessment summary [read full press release...]
Panchmukhi, India, 2026-09-05 — /EPR Network/ — Arranging a medical transport service that is completely based on the patient’s requests can help them reach their [read full press release...]
Five Dock, Australia, 2026-09-05 — /EPR Network/ — As awareness of anxiety disorders continues to grow across Australia, the Menzies Anxiety Centre remains committed to [read full press release...]
Patna, India, 2026-09-05 — /EPR Network/ — Grief can strike anyone in the form of the death of a close relative, and it can result [read full press release...]
NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company")...
As interest in whole-leaf kratom and 7-OH continues shaping buyer research in 2026, this DEFY IT Health Kratom review examines Level-Up vs. Respawn, the brand-stated *Mitragyna speciosa* ingredient profile, current pricing, batch-testing disclosures, refund terms, and the key differences consumers may want to compare before choosing a format for their routine.
Aventura attorney recognized for work in personal injury litigation and medical malpractice law for plaintiffs
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.
Amwell® is transforming virtual care delivery through its unified Amwell Platform, combining interoperability, clinical integration, and intelligent orchestration to improve access, efficiency, and outcomes. SAN ANTONIO, Sept. 4, 2026 /PRNewswire/ -- As healthcare organizations move...
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 4, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..